KeyBanc lowered the firm’s price target on Alcon (ALC) to $105 from $107 and keeps an Overweight rating on the shares. The firm remains confident in a mid to high single digit trajectory into Q4 2024 and 2025, supported by sustained market growth trends and company-specific drivers. KeyBanc believes its end markets are amongst the most resilient in MedTech and include multiple ongoing trade-ups driving healthy industry growth.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.